Boston Scientificvs.Zimmer Biomet
BSX vs ZBH · both in Medtech & devices, part of the Medicine, pharma & life science value chain: Medical equipment and devices, from surgery and cardiology to robotics.
Boston Scientific is about 3.5× larger than Zimmer Biomet by market cap; Boston Scientific trades at the lower P/E (16.5 vs 21.5); year to date, Zimmer Biomet leads (−1.6% vs −56.4%).
Side by side
| BSX | ZBH | |
|---|---|---|
| Market cap | $60.7B | $17.3B |
| Price | $42.04 | $88.88 |
| Today | +1.1% | +0.4% |
| Return YTD | −56.4% | −1.6% |
| Return 1Y | −56.6% | −10.7% |
| Since June 26, 2026 | −5.0% | −4.5% |
| P/E | 16.5 | 21.5 |
| P/S | 2.9 | 2.0 |
| P/B | 2.4 | 1.4 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Boston ScientificBSX
Cardiology drives the growth, particularly electrophysiology, where Farapulse sits, and structural heart treatment. Endoscopy and urology cover the rest of the range.
Full BSX profile →More BSX & ZBH comparisons
Other head-to-heads in the Medtech & devices segment.
See where BSX and ZBH sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →